Hydrogen sulphide donors selectively potentiate a green tea polyphenol EGCG-induced apoptosis of multiple myeloma cells

Jaehoon Bae, Motofumi Kumazoe, Shuya Yamashita & Hirofumi Tachibana

Hydrogen sulphide (H2S) is a colourless gas with the odour of rotten eggs and has recently been recognized as a signal mediator in physiological activities related with the regulation of homeostasis, the vascular system and the inflammatory system. Here we show that H2S donors, including sodium hydrogen sulphide (NaHS), GYY 4137 and diallyltrisulfide (DATS), synergistically enhanced the anti-cancer effect of a green tea polyphenol (−)-epigallocatechin-3-O-gallate (EGCG) against multiple myeloma cells without affecting normal cells. NaHS significantly potentiated the anti-cancer effect of EGCG and prolonged survival in a mouse xenograft model. In this mechanism, H2S enhanced apoptotic cell death through cyclic guanosine monophosphate (cGMP)/acid sphingomyelinase pathway induced by EGCG. Moreover, NaHS reduced the enzyme activity of cyclic nucleotide phosphodiesterase that is known as cGMP negative regulator. In conclusion, we identified H2S as a gasotransmitter that potentiates EGCG-induced cancer cell death.

Currently, there is extensive interest in the health benefits of green tea. An epidemiological study demonstrated that green tea consumption was associated with a low risk of hematologic malignancies1. The major constituent of green tea, (−)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and therapeutic effects2-4. We recently identified a 67-kDa laminin receptor (67LR) as the sensing molecule of EGCG 3, 4. Interestingly, 67LR has been shown to be overexpressed in various types of cancers4-7. Indeed, EGCG selectively kills multiple myeloma (MM) cells by targeting cancer-overexpressed 67LR4-7. Moreover, EGCG induces apoptosis by upregulating cyclic guanosine monophosphate (cGMP) in cancer cells, including MM, acute myeloid leukaemia, pancreatic cancer and prostate cancer cells4. These results demonstrate the potent and specific anti-cancer activity of EGCG and provide the rationale for its clinical evaluation7-9. However, the plasma concentration of EGCG is not enough to eradicate cancer cells.

cGMP is well known as an intracellular second messenger that mediates a number of physiological processes including cardiovascular functions, neurotransmission and anti-cancer effect. cGMP is produced by soluble guanylate cyclase (sGC). sGC is the receptor for nitric oxide (NO) that is produced by nitric oxide synthase (NOS)6-15. Cyclic nucleotide phosphodiesterases (PDEs) play a major role in cell signalling and are specifically negative regulators of cAMP and cGMP in mammalian tissues. cGMP-PDE is one of the enzymes of the PDE family and is a major inactivator of the intracellular messenger cGMP. Recently, it has been shown that specific PDE inhibitors might be new therapeutic approaches for numerous pathologies16-18. PDE5 is known to be a cGMP-specific enzyme that degrades cGMP19. PDE5 inhibitors have been shown to be effective for the treatment of erectile dysfunction20. Moreover, PDE5 inhibitor has been shown to increase cGMP-dependent apoptosis pathway in cancers4,5. There are many recent studies on the discovery of new PDE5 inhibitors for the treatment of numerous pathologies.

Several studies have demonstrated that endogenous H2S acts as a gasotransmitter similar to NO and carbon monoxide in the human body21. In this study, we used several H2S donors, such as a NaHS, GYY 4137 and diallyltrisulfide (DATS). NaHS is an inorganic sulphide salt that has been widely used as H2S equivalents in many biological studies. NaHS rapidly releases H2S under laboratory conditions. On the other hand, GYY 4137 releases...
much lesser H₂S and at a slower rate than NaHS but has shown sustained release of H₂S in a culture medium. The release mechanism of H₂S from NaHS and GYY 4127 are known to be by hydrolysis²²–²⁴. DATS is a garlic-derived sulphur compound that produces H₂S. Release of H₂S from sulphur compounds is facilitated by increasing the numbers of sulphur atoms and by allyl substituents. DATS, including trisulphides that undergo nucleophilic substitutions at the sulphur atom, then produces H₂S. The mechanism of release of H₂S from DATS is by thiol activation in which sulphur atoms react with cell membrane thiol²⁵.

There are several recent studies on the anticancer effects of H₂S donors²⁶–²⁸. H₂S donors exhibit anti-cancer activities. NaHS is reported to have anti-cancer effects through the p38 Mitogen-activated protein kinase (MAPK) signalling pathway in C6 glioma cells²⁹. GYY 4137 showed killing effects in seven human cancer cell lines and reduced tumour growth in a xenograft mouse model³⁰. Garlic-derived H₂S donor diallyl disulfide (DADS) enhanced the effect of eicosapentaenoic acid on cancer cell growth²⁹,³⁰. However, little is known about the anti-cancer mechanism of H₂S.

H₂S acts as an inhibitor of PDE that boosts cyclic nucleotide and causes vasorelaxation in vivo³¹. The present study aimed to determine the impact of H₂S on the effect of anti-cancer agents. Our study assessed the impact of H₂S on the anti-cancer effects of EGCG. We used NaHS as an H₂S donor to minimize off-target effects because the mechanisms of NaHS-derived H₂S are very simple with few by-product compared with those of other H₂S donors such as GYY 4137 and DATS.

In this study, we showed that the H₂S donor NaHS synergically potentiated the anti-MM effect of EGCG through cGMP-PDE inhibition. Furthermore, other H₂S donors GYY 4137 and DATS also significantly amplified the EGCG-elicited cGMP-dependent apoptosis-inducing signalling pathway. Combination treatment with EGCG and NaHS showed not only extended the survival period but also inhibited tumour growth in a xenograft mouse model. Collectively, our results suggest that the combination of H₂S donor and EGCG maybe a useful approach for cancer-specific chemotherapy.

**Results**

**H₂S donors potentiate EGCG-induced cancer-specific cell death.** EGCG selectively kills cancer cells by targeting the overexpression of 67LR²⁷–²⁸,³². However, the killing activity of EGCG at physiological concentration is limited³³. We assessed the anti-cancer effect of the combination of EGCG and an H₂S donor NaHS in the three MM cell lines. NaHS pretreatment significantly potentiated the anti-MM effect of EGCG, with 50% inhibitory concentrations (IC₅₀) values of 7.6 µM (U266), 3.3 µM (ARH77) and 5.4 µM (MPC-11) in the cell lines, while the IC₅₀ values for EGCG were 21.3 µM (U266), 25.8 µM (ARH77) and 21.6 µM (MPC-11) in the cell lines (Fig. 1a,b). H₂S is a gasotransmitter that regulates blood pressure³⁴ and penile erection³⁵. However, little is known about its anti-cancer effect. The IC₅₀ of NaHS was 88 µM (U266), 154.3 µM (ARH77) and 158 µM (MPC-11) in the cell lines (Supplementary Fig. 1). The isobologram plot is a well-used method for evaluating synergy based on the dose-response relationship of individual drugs. A straight line was noted on plotting the IC₅₀ doses of EGCG and NaHS on the x- and y-axes, respectively. Isobologram analysis of growth-inhibition curves revealed that the combination of EGCG and NaHS was not simply additive but was synergistic in all the three cell lines (Fig. 1a,b). The same results were obtained for other H₂S donors including GYY 4137 and DATS (Fig. 1c,d).

Selective toxicity is the most important factor in the anti-cancer effect. We found that all three H₂S donors (NaHS, GYY 4137 and DATS) and EGCG showed a significant anti-MM effect without any negative effect to normal human peripheral blood mononuclear cells (PBMCs) (Fig. 1e). Collectively, the H₂S donors synergistically potentiated the anti-MM effect of EGCG without any negative effect to normal cells.

**Combination of EGCG and NaHS induces apoptosis in MM cells.** EGCG induces apoptotic cell death in MM cells³⁴–³⁷. To investigate whether the combination of EGCG and NaHS induces apoptosis in MM cells, cells were treated with a combination of EGCG and NaHS and were stained with Annexin V–Alexa Fluor 488. These combination treatments significantly potentiated apoptosis induction in the MM cells U266, ARH77 (human MM) and MPC-11 (mouse myeloma) cells (Fig. 2a,b). Furthermore, we found that the level of cleaved caspase-3, a key mediator in apoptosis, significantly increased in EGCG/NaHS-treated human MM cells (Fig. 2c). Taken together, these findings suggest that the H₂S donor NaHS potentiates apoptosis-inducing activity of EGCG in MM cells.

**NaHS amplifies cGMP-dependent apoptosis signalling pathway.** Previously, we reported that EGCG initiated apoptosis by activating the cGMP/Protein Kinase C delta (PKCe)/Acid sphingomyelinase (ASM) axis in MM cells³⁴–³⁶. To examine the role of the cGMP-dependent cell death pathway in EGCG and NaHS combination-induced cell death, we evaluated the involvement of ASM, a downstream mediator of cGMP-elicted cell death, in MM cells. The combination of EGCG and NaHS upregulated ASM activity in MM cell lines U266, ARH77 and MPC-11 cells (Fig. 3a). In addition, the ASM inhibitor desipramine (Des) abrogated the anti-MM effect of the combination treatment of EGCG and NaHS in U266, ARH77 and MPC-11 cells (Fig. 3b). To determine the effect of NaHS on the upstream signal of cGMP, we evaluated the effect of NaHS on EGCG-elicted phosphorylation of endothelial NOS (eNOS) at Ser1177. EGCG elicited phosphorylation of eNOS at Ser1177, but NaHS did not affect the EGCG-induced phosphorylation of eNOS at Ser1177 (Fig. 3c).

PDE is a well-established negative regulator of cGMP³⁷,³⁸. Importantly, we found that NaHS reduced the enzyme activity of cGMP-PDE in U266 cells (Fig. 3d), although it did not affect the protein level of PDE5A (Supplementary Fig. 2).

Moreover, the combination of EGCG and NaHS increased cGMP levels in MM cells (Supplementary Fig. 3). H₂S can be endogenously produced in mammalian cells. We assessed the effect of EGCG on H₂S production and cystathionine γ-lyase (CSE) expression, the major enzyme involved in H₂S production³⁸. EGCG did not affect both H₂S production and CSE expression in MM cells (Supplementary Figs 4 and 5).
NaHS synergically potentiated the anti-MM effect of the NO-independent cGMP inducer Bay 41–2272 (Fig. 3e,f). To determine the effect of an H2S donor on cGMP-dependent cell death signalling, we assessed the effect of NaHS on Bay 41–2272-induced ASM activation. NaHS potentiated Bay 41–2272-elicited ASM activation in all three MM cell lines (Fig. 3g).

Taken together, these results suggest that NaHS potentiated EGCG-induced cell death through enhancement of cGMP-dependent cell death signalling in MM cells.
NaHS potentiates the anti-MM effect of EGCG in vivo. To evaluate the anti-cancer activity of the combination of EGCG and NaHS in a xenograft mouse model, MPC-11 cells were injected subcutaneously into 5-week-old BALB/c female mice. After the appearance of palpable tumours, the mice were administered intraperitoneal (i.p.) injections of EGCG (15 mg/kg/day) and/or NaHS (10 mg/kg/day) every 2 days. The combination of EGCG and NaHS resulted in significant suppression of tumour growth in the mouse model, while EGCG or NaHS alone did not show any effect on tumour growth (Fig. 4a,b). Moreover, log-rank analyses of the Kaplan–Meier survival curves showed significantly better survival among mice treated with the combination of EGCG and NaHS than among mice treated with PBS (control group), EGCG alone, or NaHS alone (Fig. 4c).

We evaluated the serum ALT/AST levels during NaHS treatment. BALB/c mice were administered intraperitoneal injections of NaHS (2.5 mg/kg/day, 5 mg/kg/day and 10 mg/kg/day) or PBS every 2 days. NaHS did not increase the serum ALT/AST levels when compared with the levels in the control group (Fig. 4d). In addition, there were no significant changes in mice tissue weights (heart, kidney, liver, spleen and lung) and mice body
weights (Supplementary Fig. 6). Furthermore, the combination of EGCG and NaHS did not increase the serum ALT/AST levels (Fig. 4e).

**EGCG and NaHS amplify the tumour apoptosis in mouse xenograft model.** We confirmed the effect of the combination of EGCG and NaHS in a tumour-bearing model based on immunofluorescence analysis. Neither EGCG (15 mg/kg/day) nor NaHS (10 mg/kg/day) caused significant induction of cleaved caspase-3 levels in tumour tissues compared with that in control group. However, the combination of EGCG and NaHS (i.p.) increased cleaved caspase-3 levels (Fig. 5a). Moreover, the combination of EGCG and NaHS significantly upregulated the ASM activity (Fig. 5b). On the other hand, EGCG elicited phosphorylation of eNOS at Ser1177, which is an upstream signal of cGMP, but NaHS did not affect the phosphorylation of eNOS at Ser1177 (Fig. 5c). We showed schematic representation indicating that H₂S donor potentiates EGCG-induced cell death pathway (Fig. 5d).
Discussion

The gasotransmitter NO is produced by eNOS and regulates sGC for cGMP production\textsuperscript{10–13}. The cGMP axis plays a key role in MM-specific cell death and mediates the MM-killing activity of EGCG\textsuperscript{4}. However, the activity of EGCG at physiological concentrations is limited in MM cells\textsuperscript{33}.

Here we showed that H\textsubscript{2}S donors, including NaHS, GYY\textsubscript{4137} and DATS, potentiate EGCG-induced cell death in MM cells. Moreover, the combination of EGCG and H\textsubscript{2}S donor extended the survival time and reduced the tumour volume in a xenograft mouse model.

Several studies have reported the growth-suppressing and apoptosis-inducing effects of H\textsubscript{2}S or H\textsubscript{2}S donors through the Bax, Blc-X and p38 MAPK signalling pathways\textsuperscript{26–29}. In our study, three different H\textsubscript{2}S inducers strongly potentiated EGCG-induced cell death at very low concentrations (H\textsubscript{2}S donor 10\textmu M in vitro; NaHS, 10 mg/kg body weight in vivo) than those that are enough to induce anti-cancer effects (NaHS, approximately 200–1000\textmu M in vitro; GYY4131, 100–300 mg/kg/day). In this study, we observed that the H\textsubscript{2}S donor NaHS suppressed the enzyme activity of cGMP-PDE, the negative regulator of cGMP. Moreover, NaHS potentiated EGCG-induced cGMP production level.

Activation of the ASM axis is an essential mediator in cGMP-initiated apoptosis\textsuperscript{4, 7}. Our data also showed that the ASM activity and cleaved caspase-3 levels increased in tumour tissues of mice treated with combination of EGCG and NaHS compared with those in control group. In contrast, compared with control group, EGCG or NaHS alone did not affect both ASM activity and cleaved caspase-3 levels. Furthermore, we confirmed that the H\textsubscript{2}S donor potentiated ASM activation induced by Bay 41–2272, a NO-independent sGC activator. The EGCG-induced eNOS/cGMP/ASM/caspase-3 axis plays an important role in MM cell death\textsuperscript{4}. Single NaHS treatment does not appear to induce phosphorylation of eNOS at Ser1177 in vitro and in vivo. We also confirmed that NaHS did not have an impact on EGCG-elicited phosphorylation of eNOS at Ser1177. These results suggest that H\textsubscript{2}S donor potentiates the anti-MM effect of EGCG by enhancing the downstream of cGMP but not affecting eNOS phosphorylation at Ser1177. Moreover, H\textsubscript{2}S is known as an inhibitor of PDE5 activity\textsuperscript{35}. Furthermore, EGCG did not affect H\textsubscript{2}S production in MM cells. These results suggest that intracellular H\textsubscript{2}S produced by NaHS potentiates EGCG-induced anti-MM effect via inhibition of cGMP-PDE enzyme activity.

We also showed that H\textsubscript{2}S donors dramatically potentiated the anti-cancer effects of EGCG at a physiological concentration without affecting normal PBMCs. With regard to efficient chemotherapy, novel therapeutic drugs with different mechanisms and highly selective toxicity are required. Hepatotoxicity is a well-known adverse effect of high-dose EGCG\textsuperscript{38} and, in some cases, elevation of the transaminases ALT and AST has been observed in...
Importantly, the combination of EGCG and NaHS did not increase the serum ALT/AST levels, suggesting that an H2S donor could be a potent candidate to enhance the pharmacological effect of EGCG without enhancing its adverse effects.

In conclusion, H2S donor potentiates the anti-MM effect of EGCG at a physiological concentration. The combination of EGCG and an H2S donor could provide a novel strategy for MM treatment without affecting normal PBMCs. Moreover, our data suggest that H2S may potentiate the downstream mediators of EGCG-induced apoptosis along with the inhibition of cGMP-PDE enzyme activity. PDE5 overexpressed in many types of cancer cells, such as a chronic lymphocytic leukaemia, acute myeloid leukaemia, stomach cancer, pancreatic cancer, prostate cancer, breast cancer and MM cells. EGCG and PDE5 inhibitor in combination also induce apoptotic cell death in these cancer cells. Taken together, we suggest that H2S donor and EGCG in combination could be effective for chemotherapy and have high potential for use in various types of cancers including MM.

**Materials and Methods**

**Cell culture.** Primary PBMCs were provided by Takara (Siga, Japan). U266, ARH77 (human MM) and MPC-11 (mouse myeloma) cell lines were cultured in RPMI 1640 supplemented with 10% (v/v) foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO2 and 100% humidity.

MM cells were seeded into 24-well plates at a seeding density of 5 × 10⁴ cells/well and were then treated with drugs at various concentrations or indicated periods in RPMI 1640 medium supplemented with 1% FBS, 200 U/ml catalase and 5 U/ml superoxide dismutase (SOD) (Sigma-Aldrich).
Cell viability was evaluated using trypan-blue exclusion. Apoptotic cells were detected by using the Alexa Fluor 488 Annexin V apoptosis detection kit (Invitrogen). Cells were suspended in Annexin V–Alexa Fluor 488 and Annexin V binding buffer. A portion of the cell suspension was then placed onto a glass slide. All images of in vitro experiments were acquired using a fluorescence microscope (BZ-9100; Keyence). For flow cytometric analyses, the percentages of Annexin-V^+ cells were calculated by combining Annexin-V^+/PI^+ (early apoptosis) and Annexin-V^+/PI^- (late apoptosis) cells, followed by analyses on a Versa™ system (Perkin–Elmer). Measurement of ASM activity was performed as described previously.

Evaluation of intracellular cGMP was performed by using the cGMP assay kit (Cayman Chemicals), according to the manufacturer’s protocol. Analysis was carried out by using the Envision™ Plate Reader (Perkin–Elmer).

**Immunoblot analysis.** Cells were lysed in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 50 mM NaF, 30 mM Na_4P_2O_7, 1 mM phenylmethanesulfonyl fluoride, 2 mg/ml aprotinin and 1 mM pefabloc.

Approximately 50 μg protein was suspended in Laemmli sample buffer (0.1 M Tris-HCl buffer, pH 6.8; 1% SDS; 0.05% mercaptoethanol; 10% glycerol and 0.001% bromophenol blue), boiled, and electrophoresed on SDS–polyacrylamide gels. SDS gels were then electrophroresed onto Trans-Blot nitrocellulose membranes (Bio-Rad). Blots were incubated with the indicated antibodies in Tween 20–PBS (TBBS) containing 1% BSA. The blots were then washed with TBBS and incubated with anti-rabbit or anti-mouse HRP conjugates. After washing, specific proteins were detected using an enhanced chemiluminescence system according to a manual from Amersham Life Sciences.

**Xenograft murine model.** Five-week-old female BALB/c mice were obtained from Kyudo (Fukuoka, Japan). Mice were inoculated subcutaneously in the interscapular area with 1 × 10^6 MPC-11 cells in 200 μl of RPMI 1640 medium. Following the appearance of palpable tumours, the mice were injected with saline alone, or EGCG (15 mg/kg) or NaHS (10 mg/kg) every 2 days. The tumour sizes were evaluated by using callipers, and their volumes were calculated as (length) × (width)^2 × 0.5. All animal studies were performed in accordance with the law (protocol no. 105) and notification (protocol no. 6) of the Japanese government for the welfare of experimental animals. The study protocol was approved by the Animal Care Committee.

Immunofluorescent staining experiments were performed by using a fluorescence microscope (BZ-9000; Keyence). Briefly, anti-cleaved caspase-3 antibodies (D175) (Cell Signalling Technology) were used at 1:300 dilution and incubated for 1 hour. Slides were then treated with Alexa Fluor 488–conjugated secondary antibody (Invitrogen) at 1:300 dilution and incubated for 1 hour. To evaluate the effect of NaHS, mice were injected with saline alone or indicated NaHS (1 p. i.) every 2 days for 8 weeks. At the end of 8 weeks of treatment, the mice were anaesthetized under isoflurane vapour after overnight food deprivation and each organ were weighed and the serum ALT and AST levels were evaluated. The AST and ALT quantification kits were purchased from Wako (Osaka, Japan).

**Statistical analysis.** All data are expressed as mean ± SEM. The IC_{50} value calculation and isobologram analysis were performed by using the Calcusyn 2.0 software (Biosoft). The significance of differences between experimental variables was determined using Tukey’s test. Statistical analyses were performed using the KyPlot software (Kyens Lab, Tokyo, Japan). Survival was assessed using the log-rank test for Kaplan–Meier curves. A P-value < 0.05 was considered significant.

**References**

1. Naganuma, T. et al. Green tea consumption and hematologic malignancies in Japan: the Ohsaki study. *Am. J. Epidemiol.* **170**, 30–738 (2009).
2. Tachibana, H., Koga, K., Fujimura, Y. & Yamada, K. A receptor for green tea polyphenol EGCG. *Nat. Struct. Mol. Biol.* **11**, 380–381 (2004).
3. Tsukamoto, S. et al. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive α2β1 integrin. *J. Biol. Chem.* **279**, 23414–23423 (2004).
4. Kumazoe, M. et al. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. *J. Pharmacol. Exp. Ther.* **(2005)** 314, 9–15 (2005).
5. Tsukamoto, S. et al. Green tea polyphenol EGCG induces lipid-raft clustering and apoptotic cell death by activating protein kinase Cδ and acid sphingomyelinase through a 67 kDa laminin receptor in multiple myeloma cells. *Biochem. J.* **443**, 525–534 (2012).
6. Tsukamoto, S. et al. 67 kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance. *J. Biol. Chem.* **289**, 32671–32681 (2014).
7. Yamada, S. et al. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. *Sci. Rep.* **6**, 19225 (2016).
8. Linder, A. E., McCluskey, L. P., Cole, K. R., Lanning, K. M. & Webb, R. C. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. *J. Pharmacol. Exp. Ther.* **(2005)** 314, 9–15 (2005).
9. Russwurm, M., Wittau, N. & Koessler, D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. *J. Biol. Chem.* **276**, 44647–44652 (2001).
10. Schoser, B. G. & Behrends, S. Soluble guanylyl cyclase is localized at the neuromuscular junction in human skeletal muscle. *Neuroreport* **12**, 979–981 (2001).
11. Zabel, U. et al. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. *Nat. Cell Biol.* **4**, 307–311 (2002).
12. Warner, T. D., Mitchell, J. A., Sheng, H. & Murad, F. Effects of cyclic GMP on smooth muscle relaxation. *Adv. Pharmacol.* **26**, 171–194 (1994).
13. Ivanova, K. et al. Soluble guanylyl cyclase and platelet function. *Annals of the New York Academy of Sciences.* **714**, 151–157 (1994).
16. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. *Pharmacol. Ther.* **109**, 366–398 (2006).

17. Keravis, T. & Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. *Br. J. Pharmacol.* **165**, 1288–1305 (2012).

18. Porst, H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. *Int. J. Impot. Res.* **13**, 192–199 (2001).

19. Loughney, K. et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. *Gene* **216**, 139–147 (1998).

20. Huang, S. A. & Lie, J. D. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. *Pharma. Ther.* **38**, 407 (2013).

Paul, B. D. & Snyder, S. H. H2S signalling through protein sulphhydration and beyond. *Nat. Rev. Mol. Cell Biol.* **13**, 499–507 (2012).

22. Lee, Z. W. et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. *PLoS One* **6**, e21077 (2011).

23. Li, L. et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. *Circulation* **117**, 2351–2360 (2008).

24. Zhao, Y., Biggs, T. D. & Xian, M. Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications. *Chem. Commun.* **50**, 11788–11805 (2014).

25. Benavides, G. A. et al. Hydrogen sulfide mediates the vasoactivity of garlic. *Proc. Natl. Acad. Sci. USA* **104**, 17977 (2007).

26. Zhao, L. et al. Exogenous hydrogen sulfide exhibits anti-cancer effects though p38 MAPK signaling pathway in C6 glioma cells. *Biol. Chem.* **396**, 1247–1253 (2015).

27. Lee, Z. W. & Deng, L. W. Role of H2S Donors in Cancer Biology. *Handb Exp Pharmacol.* **230**, 243–265 (2015).

28. De Preter, G. et al. A Fast Hydrogen Sulfide-Releasing Donor Increases the Tumor Response to Radiotherapy. *Mol. Cancer Ther.* **15**, 154–161 (2016).

29. Nakagawa, H. et al. Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines. *Carcinogenesis* **22**, 891–897 (2001).

30. Tsuhara, A., Lal, Y. C., Kuvata, M., Uehara, N. & Yoshizawa, K. Anticancer effects of garlic and garlic-derived compounds for breast cancer control. *Anticancer Agents Med Chem.* **11**, 249–253 (2011).

31. Bucci, M. et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler. Thromb. Vasc. Biol.* **30**, 1998–2004 (2010).

32. Kumazoe, M. et al. Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis. *FEBS Lett.* **587**, 3052–3057 (2013).

33. Shanafelt, T. D. et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. *J. Clin. Oncol.* **27**, 3808–3814 (2009).

34. Mustafa, A. K. et al. H2S signals through protein S-sulfhydration. *Sci. Signal.* **2**, ra72 (2009).

35. Qu, X., Villalta, J., Lin, G. & Lue, T. F. Role of hydrogen sulfide in the physiology of penile erection. *J. Androl.* **33**, 529–535 (2012).

36. Huang, X. et al. Green tea polyphenol epigallocatechin-3-gallate induces cell death by acid sphingomyelinase activation in chronic myeloid leukemia cells. *Oncol. Rep.* **34**, 1162–1168 (2015).

37. Kabil, O., Vitvitsky, V., Xie, P. & Banerjee, R. The quantitative significance of the transsulfuration enzymes for H2S production in murine tissues. *Antioxid Redox Signal.* **15**, 363–372 (2011).

38. Lambert, J. D. et al. Hepatotoxicity of high oral dose (−)-epigallocatechin-3-gallate in mice. *Food Chem. Toxicol.* **48**, 409–416 (2010).

39. Shanafelt, T. D. et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. *Cancer* **119**, 363–370 (2013).

Acknowledgements
This work was supported in part by JSPS KAKENHI grant 22228002 and 15H02448 to H. Tachibana.

Author Contributions
J.B. and M.K. performed the experiments and J.B. and M.K. analysed the data and have the responsibility for integrity of whole data. J.B., M.K. and H.T. conducted the research. B.J., M.K., S.Y. and H.T. wrote the paper. H.T. had primary responsibility for the final content. All authors have reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-06879-5

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017